oestrone-3-phenylphosphonate | 147725-58-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: oestrone-3-phenylphosphonate
• 英文别名: [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl]oxy-phenylphosphinic acid
• CAS: 147725-58-4
• 化学式: C₂₄H₂₇O₄P
• 分子量: 410.45
• InChiKey: JCFSJJVFJNLAKD-SVPADUAOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Estra-1,3,5 (10)-triene derivatives
  申请人：——

  公开号：US20030216362A1

  公开（公告）日：2003-11-20

  Provided is steroid sulfatase inhibitors comprising, as the active ingredient, an estra-1,3,5(10)-triene derivative which is represented by formula (I): 1 {wherein R 1 and R 2 are the same or different and represent a hydrogen atom, a lower alkyl group or, etc.; R 3 represents a hydrogen atom etc.; R 4 represents a hydrogen atom etc.; R 5 represents a hydrogen atom etc.; R 6 represents a cyano group, an amino group, COR 53 (wherein R 53 represents a substituted lower alkyl group etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, etc}, or pharmaceutically acceptable salts thereof.

  提供的类固醇磺酸酶抑制剂包括作为活性成分的酮基-1,3,5(10)-三烯衍生物，其由式(I)表示：1{其中R1和R2相同或不同，表示氢原子、较低的烷基基团等；R3表示氢原子等；R4表示氢原子等；R5表示氢原子等；R6表示氰基、氨基、COR53(其中R53表示取代的较低烷基基团等)、取代或未取代的芳基团、取代或未取代的杂环基团等，或其药用盐。
• Estra-1,3,5(10), 16-tetraene derivatives
  申请人：——

  公开号：US20020058651A1

  公开（公告）日：2002-05-16

  Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): 1 (wherein R 1 represents hydroxy, alkoxy, or NR 2 R (wherein R 2 and R 3 are the same or different, and each represents hydrogen, straight-chain lower alkyl having 1 to 3 carbon atoms, or branched-chain lower alkyl having 3 to 8 carbon atoms)), or pharmaceutically acceptable salts thereof.

  以下是Estra-1,3,5(10),16-tetraene衍生物的化学式（I）： 其中，R1代表羟基、烷氧基或NR2R（其中R2和R3相同或不同，且每个代表氢、1至3个碳原子的直链低碳基或3至8个碳原子的支链低碳基），或其药学上可接受的盐。
• ESTRA-1,3,5(10)-TRIENE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1284272A1

  公开（公告）日：2003-02-19

  Provided is steroid sulfatase inhibitors comprising, as the active ingredient, an estra-1,3,5(10)-triene derivative which is represented by formula (I): wherein R1 and R2 are the same or different and represent a hydrogen atom, a lower alkyl group or, etc.; R3 represents a hydrogen atom etc.; R4 represents a hydrogen atom etc.; R5 represents a hydrogen atom etc.; R6 represents a cyano group, an amino group, COR53 (wherein R53 represents a substituted lower alkyl group etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, etc}, or pharmaceutically acceptable salts thereof.

  本发明提供了甾体硫酸酯酶抑制剂，其活性成分包括由式(I)表示的雌甾-1,3,5(10)-三烯衍生物： 其中R1和R2相同或不同，代表氢原子、低级烷基或等；R3代表氢原子等；R4代表氢原子等；R5代表氢原子等；R6代表氰基、氨基、COR53（其中R53代表取代的低级烷基等）、取代或未取代的芳基、取代或未取代的杂环基等}，或其药学上可接受的盐。
• REMEDY FOR HORMONE-DEPENDENT CANCER
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1568381A1

  公开（公告）日：2005-08-31

  A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.

  本发明提供了一种激素依赖性癌症的治疗剂，它包括(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂，这两种药物可以一起给药，也可以间隔一段时间分别给药。还提供了一种治疗激素依赖性癌症的方法，该方法包括(a)类固醇-硫酸酯酶抑制剂和(b)激素治疗制剂和/或化疗制剂，它们可以一起给药，也可以间隔一段时间分别给药。还提供了一种类固醇硫酸酯酶抑制剂，该抑制剂与激素治疗剂和/或化疗剂联合使用，并在一定间隔时间内一起或分开给药。还提供了一种用于治疗激素依赖性癌症的试剂盒，它包括由(a)类固醇硫酸酯酶抑制剂组成的第一组分和由(b)激素治疗剂和/或化疗剂组成的第二组分。还提供了一种药物组合物，它包含(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂。此外，还提供了使用(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂制造激素依赖性癌症治疗剂的方法。
• STEROID SULPHATASE INHIBITORS
  申请人：Sterix Limited

  公开号：EP0602123B1

  公开（公告）日：2000-03-29